Support for a Biotech Company entering the french market with an orphan drug.
Through stakeholder engagement with NICE, clinical experts, the patient advocacy group, civil servants and members of the UK Parliament, MAP was able to redirect the product into the NICE Highly Specialised Technology (HST) programme. MAP then supported the company to achieve an acceptable price with the Department of Health and Social Care, and develop real world evidence to supplement the pivotal clinical trials which, combined into a submission and model developed by MAP, led to a positive NICE guidance and broad uptake by the NHS.
We are pioneers in the utilisation of Multi-Criteria Decision Analysis (MCDA) at international and national level, helping evaluation committees to assess the relative additional value contribution of new health technology and helping companies to better position their product with respect to existing alternatives.
RPN has experience with a wide range of therapeutic areas and particularly with orphan and advanced-therapy medicinal products. RPN support includes early access and P&MA strategic assessments, advisory boards, stakeholder management and full support with national and regional P&R negotiations.
SmartStep Healthcare Strategy & Market Access Consulting provides personalized and specialized consulting services to the pharmaceutical and medical device industries to provide fast and effective market access to their products in Germany.